|  |
| --- |
| **Quality Impact Assessment (QIA)** |
| **1. DETAILS** |
| **CIP No.** *(ref. CIP tracker)* |  |
| **Scheme Title:** |  |
| **Month of Delivery:***NB: QIA sign-off* ***must*** *precede this date.* |  |
| **Project Lead:** |  |
| **Directorate:** |  |
| **Project Overview and Objectives:** *The overview should provide sufficient information without the need to refer to other documentation* |  |
| **Financial Benefits** *(savings in £000s) Recurring/Non-recurring*: | **FYE:**  | **PYE:**  |
|  |
| **2. RAPID ASSESSMENT (*to be completed for all CIPs*):** |
| ***If you answer YES to any of these questions a full impact assessment is required – please complete section 3 below*** | **Is the scheme going to impact on workforce?**  |
| **Is the scheme going to impact on service delivery?**  |
| **Is the financial benefit over £50k?**  |
| **Does the initial risk review for the overall project score 4 or above ?(*circle matrix below*)**  |
| **Is a full QIA required?** *(If NO, please send a signed copy of this report to the PMO – if YES please complete section 3)****NB: both rapid assessments and full QIAs require Head of Nursing and CD/Exec lead and Head of Department signatures***  |
| **Print Name and Title: Signature:**   |
|  |
| **3. FULL IMPACT ASSESSMENT:** |
| **All sections must be complete** | **Impact Details** (include mitigation / control – *do these measures address the risk*?) **SCORE EACH RISK LISTED**  | **Consequence** | **Likelihood** | **Score** |
| **Risk to Patient Safety***Does the project have the potential to impact on the safety of patients, staff or any other person?* | **Risk:** |  |  |  |
| **Mitigation:** |
| **Risk to Clinical Effectiveness** *Have clinicians been involved in developing the project? Is there evidence to support the project (case studies, best practice, NICE guidelines etc.)?*  | **Risk:** |  |  |  |
| **Mitigation:** |
| **Risk to Patient Experience** – *Consider healthcare environment, dignity and respect of patients, families and carers etc. waiting times, access to services, equality and diversity*  | **Risk:** |  |  |  |
| **Mitigation:** |
| **Overall risk score:** |
| **Scores over 12 must be added to the Directorate Risk Register** | **Datix reference:** |
| **Benefit for patients:** |  |
| **Key Quality Indicators (KQIs):** | *(detail any performance measures or KPIs that will be used to monitor the impact of this scheme)* |
| **Interdependencies with/support required from other departments:***Eg. Other directorates/IT/HR etc.*  | *(Provide overview and discussion with other areas)* |
| **Discussed at DMT meeting:** | Date: |
| **Date of meeting at which QIA will be formally reviewed** : | Date: |
| **SIGNATURES:** |
| **NON-PAY ONLY** **Approved by Clinical Sponsor:**Name & Designation:Date: | Signature: |
| **Approved by CLINICAL DIRECTOR *or* EXECUTIVE LEAD for Facilities/Corporate Directorates:** Name: Date: | Signature:  |
| **Approved by HEAD OF NURSING *or* HEAD OF DEPARTMENT for Facilities/Corporate Directorates:**Name: Date: | Signature:  |
| **PLEASE SEND TO PMO FOR FURTHER SIGNATURES** |
| **FOR COMPLETION BY THE MEDICAL DIRECTOR AND DIRECTOR OR NURSING** |
| **Does the QIA require escalation to the Transformation Board?** *(please circle)* **Y N***(If NO, please sign below and return to the PMO – if YES please return to the PMO who will ask for the document to be added to the Transformation Board agenda)* |
| **IF ESCALATION IS NOT REQUIRED:****Approved by Medical Director:** Signature: Date: **Approved by Director of Nursing:** Signature: Date: |
| **PLEASE RETURN TO PMO** |
| **IF ESCALATION TO TRANSFORMATION BOARD IS REQUIRED** **Date of Transformation Board meeting at which QIA was discussed:** |
| **QIA approved by the Chair of Transformation Board:**Signature: Date: |
| **PLEASE RETURN TO PMO** |

|  |
| --- |
| **6 MONTH POST IMPLEMENTATION REVIEW**  |
| **CIP No. (ref. CIP tracker)** |  |
| **QIA was reviewed formally at the following meeting/s:** *The purpose of the subsequent reviews is to ensure that proposed mitigating actions or other measures are put in place and are effective in managing risks to quality.* |  |
| **Have the risks identified in the QIA been mitigated? Provide evidence against each KQI (key quality indicator).***Reference the KQIs from the original quality impact assessment and describe the impact this scheme has had on them.*  |  |
| **Have you identified any further risks or unintended adverse consequences of the implementation of this scheme? How will these be/were these managed?***What scheme amendments or other measures will you implement to mitigate this risk?*  | **New Risk:** |
| **New Mitigation:** |
| **A) What impact is this scheme having on the quality of service delivery?**(i.e. Reducing, Improving or Maintaining Quality) *Please specify which aspect of your service has been affected.***B) Do you consider this to be acceptable and sustainable?** *(Please give your reasoning).* |  |
| **DMT Recommendations:** *(eg. continue/cease change etc)* |
| **Approved by CLINICAL DIRECTOR or EXECUTIVE LEAD for Facilities/Corporate Directorates:** Name: Date: | Signature:  |
| **Approved by HEAD OF NURSING or HEAD OF DEPARTMENT for Facilities/Corporate Directorates:**Name: Date:  | Signature:  |
| **PLEASE SEND TO PMO FOR FURTHER SIGNATURES** |
| **FOR COMPLETION BY THE MEDICAL DIRECTOR AND DIRECTOR OR NURSING** |
| **Does the QIA review require escalation to the Transformation Board?***(please circle)* **Y N***(If NO, please sign below and return to the PMO – if YES please return to the PMO who will ask for the document to be added to the Transformation Board agenda)* |
| **IF ESCALATION IS NOT REQUIRED:****Approved by Medical Director:** Signature: Date:**Approved by Director of Nursing:** Signature: Date: |
| **PLEASE RETURN TO PMO** |
| **IF ESCALATION TO TRANSFORMATION BOARD IS REQUIRED - Date of Transformation Board meeting at which QIA was discussed:** |
| **QIA approved by the Chair of Transformation Board:** Signature: Date: |
| **PLEASE RETURN TO PMO** |